| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: 2410GDU/g
| Targets |
Bromelain targets proteins, hydrolyzing peptide bonds through its proteolytic activity. It has anti-inflammatory effects by modulating the production of inflammatory mediators such as prostaglandins and cytokines. Bromelain also has antithrombotic and fibrinolytic activities by degrading fibrin and other coagulation factors.
|
|---|---|
| ln Vitro |
Bromelain demonstrates in vitro proteolytic activity, hydrolyzing various protein substrates. It exhibits anti-inflammatory activity by modulating cytokine production and reducing inflammation in cell-based assays. The compound's activity is assessed by measuring its proteolytic activity using protein substrates or by measuring its effects on inflammatory markers.
|
| ln Vivo |
In a rat model of Parkinson's disease (PD), pretreatment with bromelain (40 mg/kg; intraperitoneal injection; daily; for 7 days; male Sprague-Dawley rats) decreases motor dysfunction. Significant motor damage is caused by 6-OHDA injections, however this can be avoided by administering bromelain prior to injury [1].
In vivo activity of bromelain has been demonstrated in animal models, where it exhibits anti-inflammatory, antithrombotic, and fibrinolytic effects. It is used in research on wound healing, inflammation, and cardiovascular diseases. Bromelain has also been studied for its potential benefits in digestion and as a dietary supplement. |
| Enzyme Assay |
In vitro enzyme assays for bromelain involve measuring its proteolytic activity using protein substrates such as casein, gelatin, or synthetic peptide substrates. Enzyme activity is measured by detecting the release of hydrolysis products using spectrophotometric or fluorometric methods.
|
| Cell Assay |
In vitro cellular assays for bromelain involve treating cells with the enzyme and measuring its effects on inflammatory mediators, cell migration, or protein degradation. Anti-inflammatory activity is assessed by measuring cytokine production. Wound healing effects can be assessed by measuring cell migration in scratch wound assays.
|
| Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) rats injected with 6-OHDA[1]
Doses: 40 mg/kg Route of Administration: intraperitoneal (ip)injection; daily; for 7 days Experimental Results: diminished the motor dysfunction in the parkinsonian rat model of parkinson's disease (PD). In vivo animal experiments for bromelain involve administering the enzyme to animal models of inflammation, thrombosis, or wound healing. Efficacy is evaluated by measuring inflammatory markers, thrombus formation, or wound closure rates. The enzyme's fibrinolytic activity can be assessed by measuring fibrin degradation products. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for bromelain indicate that it is absorbed from the gastrointestinal tract and can be detected in the circulation. The enzyme's proteolytic activity is stable in the acidic environment of the stomach. Its distribution, metabolism, and excretion properties have been partially characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for bromelain indicate that it is generally safe when used at recommended doses. Allergic reactions may occur in sensitive individuals. The compound is intended for research and dietary supplement use. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Bromelain (CAS#: 9001-00-7) is a mixture of proteolytic enzymes derived from pineapple (Ananas comosus). It is a cysteine endopeptidase with anti-inflammatory, antithrombotic, and fibrinolytic activities. Bromelain is used in research on inflammation, wound healing, and digestion. It is also used as a dietary supplement.
|
| Molecular Weight |
0
|
|---|---|
| Exact Mass |
226.106
|
| CAS # |
9001-00-7
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
656.2±55.0 °C at 760 mmHg
|
| Flash Point |
350.7±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
-2.17
|
| SMILES |
O([C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](CO[C@@H]2[C@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)O1)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O)NC(C)=O)[C@@H]1[C@@H](CO)OC([C@@H]([C@H]1O[C@H]1[C@H]([C@@H]([C@@H]([C@H](C)O1)O)O)O)NC(C)=O)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 6.67 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA